Details

Autor(en) / Beteiligte

• Lueschow-Guijosa, Shiloh R.
• Stanford, Amy H.
• Berger, Jennifer N.
• Gong, Huiyu
• Boly, Timothy J.
• Jensen, Benjamin A.H.
• Nordkild, Peter
• Leegwater, Alexandra J.
• Wehkamp, Jan
• Underwood, Mark A.
• McElroy, Steven J.

Titel

Host defense peptides human β defensin 2 and LL-37 ameliorate murine necrotizing enterocolitis

Ist Teil von

• iScience, 2024-06, Vol.27 (6), p.109993, Article 109993

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Necrotizing enterocolitis (NEC) is a leading cause of preterm infant morbidity and mortality. Treatment for NEC is limited and non-targeted, which makes new treatment and prevention strategies critical. Host defense peptides (HDPs) are essential components of the innate immune system and have multifactorial mechanisms in host defense. LL-37 and hBD2 are two HDPs that have been shown in prior literature to protect from neonatal sepsis-induced mortality or adult inflammatory bowel disease, respectively. Therefore, this article sought to understand if these two HDPs could influence NEC severity in murine preclinical models. NEC was induced in P14-16 C57Bl/6 mice and HDPs were provided as a pretreatment or treatment. Both LL-37 and hBD2 resulted in decreased NEC injury scores as a treatment and hBD2 as a pretreatment. Our data suggest LL-37 functions through antimicrobial properties, while hBD2 functions through decreases in inflammation and improvement of intestinal barrier integrity. [Display omitted] •Host defense peptides LL-37 and hBD2 reduce NEC-like murine injury•LL-37 acts through antimicrobial and wound-healing mechanisms•HBD2 acts through immunomodulation and wound healing mechanisms•HBD2 has a better biosafety profile than LL-37 Biological sciences; Molecular biology; Immunology